Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Inves

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. SPY
3. ABBV
4. META
5. FDX
6. IBM
7. MU
8. PFE
9. ACN
10. USO

Go back to Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Inves
(NASDAQ: VRCA) Delayed: 5.65 +0.01 (0.18%)
Previous Close $5.64    52 Week High $ 
Open $5.46    52 Week Low $ 
Day High $5.92    P/E N/A 
Day Low $5.30    EPS $ 
Volume 34,302